Trastuzumab deruxtecan (T-DXd) in HER2-expressing gynecological malignancies: Clinical evidence, safety profile, and future directions

Heena Arshad, Inamullah Arshad, Hamza Massab Rehman, Safia Bibi, Muhammad Hassaan Javaid, Ruben Simon Roy · 2026

Read Trastuzumab deruxtecan (T-DXd) in HER2-expressing gynecological malignancies: Clinical evidence, safety profile, and future directions by Heena Arshad, Inamullah Arshad, Hamza Massab Rehman, Safia Bibi, Muhammad Hassaan Javaid, Ruben Simon Roy (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13251781.txt.

Description

Heena Arshad and co-authors review trastuzumab deruxtecan, a targeted cancer drug, in gynecological cancers in 2026. The drug couples an antibody that homes in on the HER2 protein with a chemotherapy payload it delivers into tumor cells. Advanced cancers of the ovary, cervix, and womb lining still carry poor outlooks once standard treatment fails, so biomarker-guided options are badly needed.

Trial evidence gathered in the review shows the strongest responses in tumors with the highest HER2 levels on standard staining tests. A multi-tumor study supports using HER2 status, rather than cancer type alone, to select patients. The review gives special weight to interstitial lung disease, a serious lung inflammation linked to the drug that demands early detection and fast action. Careful HER2 testing before treatment is presented as essential. The authors also survey ongoing trials that may move the drug into earlier treatment lines.

Catalog record

CREATORHeena Arshad, Inamullah Arshad, Hamza Massab Rehman, Safia Bibi, Muhammad Hassaan Javaid, Ruben Simon Roy
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE54 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13251781

Browse the full library · About the Tower of Babel